KR20250024104A - 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 - Google Patents

다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 Download PDF

Info

Publication number
KR20250024104A
KR20250024104A KR1020257003259A KR20257003259A KR20250024104A KR 20250024104 A KR20250024104 A KR 20250024104A KR 1020257003259 A KR1020257003259 A KR 1020257003259A KR 20257003259 A KR20257003259 A KR 20257003259A KR 20250024104 A KR20250024104 A KR 20250024104A
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257003259A
Other languages
English (en)
Korean (ko)
Inventor
이 주
올레 올슨
동 시아
데이비드 젤리맨
카트리나 비코바
앤-마리 루소
빌 브래디
블레어 렌쇼
브라이언 코바세비치
유 리앙
제렌 가오
Original Assignee
시스트이뮨, 인코포레이티드
바이리-바이오 (청두) 파마슈티칼 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시스트이뮨, 인코포레이티드, 바이리-바이오 (청두) 파마슈티칼 컴퍼니, 리미티드 filed Critical 시스트이뮨, 인코포레이티드
Publication of KR20250024104A publication Critical patent/KR20250024104A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020257003259A 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 Pending KR20250024104A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762524557P 2017-06-25 2017-06-25
US62/524,557 2017-06-25
KR1020207002328A KR102763369B1 (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
PCT/US2018/039156 WO2019005639A2 (en) 2017-06-25 2018-06-22 MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002328A Division KR102763369B1 (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20250024104A true KR20250024104A (ko) 2025-02-18

Family

ID=64742644

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257003259A Pending KR20250024104A (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
KR1020207002328A Active KR102763369B1 (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207002328A Active KR102763369B1 (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도

Country Status (10)

Country Link
US (1) US11787863B2 (https=)
EP (1) EP3645049A4 (https=)
JP (1) JP7399852B2 (https=)
KR (2) KR20250024104A (https=)
CN (4) CN116948035A (https=)
AU (2) AU2018295118B2 (https=)
CA (1) CA3068045A1 (https=)
IL (2) IL313468A (https=)
SG (1) SG11201912864SA (https=)
WO (1) WO2019005639A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250376531A9 (en) * 2017-06-25 2025-12-11 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
EP3645738A4 (en) * 2017-06-25 2021-08-18 Systimmune, Inc. ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
CN114502203B (zh) * 2019-11-06 2024-07-19 成都百利多特生物药业有限责任公司 制导和导航控制蛋白及其制备和使用方法
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
JP2025512953A (ja) * 2022-04-11 2025-04-22 アストラゼネカ・アクチエボラーグ Ｔ細胞結合タンパク質
AU2023409023A1 (en) * 2022-12-20 2025-07-31 Ho'ola Therapeutics Inc. Combination therapies for the treatment of cancer
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
CN116143934B (zh) * 2023-03-21 2023-07-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞外泌体提取试剂盒及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392359B2 (en) * 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
PE20091420A1 (es) 2007-11-13 2009-10-17 Evec Inc ANTICUERPOS MONOCLONALES ANTI hGM-CSF
US9365644B2 (en) 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
TW201100543A (en) * 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
CA2854806A1 (en) * 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
EP3013864A1 (en) 2013-06-26 2016-05-04 Numab AG Novel antibody frameworks
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
JP2016539632A (ja) * 2013-10-25 2016-12-22 ヌマブ アクチェンゲゼルシャフト 二重特異性構築物と種々の疾患の治療におけるその使用
CA2940242C (en) 2014-02-20 2026-01-13 H. Lundbeck A/S Anti-acth antibodies and use thereof
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
JP6932700B2 (ja) * 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins

Also Published As

Publication number Publication date
KR20200092301A (ko) 2020-08-03
CN116948035A (zh) 2023-10-27
IL271257B1 (en) 2024-07-01
AU2018295118A1 (en) 2020-02-06
CN116199785A (zh) 2023-06-02
SG11201912864SA (en) 2020-01-30
KR102763369B1 (ko) 2025-02-05
WO2019005639A3 (en) 2019-02-07
JP7399852B2 (ja) 2023-12-18
IL271257A (en) 2020-01-30
JP2020530777A (ja) 2020-10-29
US20220002406A1 (en) 2022-01-06
CN110831973A (zh) 2020-02-21
RU2020102662A (ru) 2021-07-27
EP3645049A2 (en) 2020-05-06
US11787863B2 (en) 2023-10-17
NZ760913A (en) 2024-10-25
EP3645049A4 (en) 2021-06-30
IL313468A (en) 2024-08-01
AU2025204860A1 (en) 2025-07-17
CN110831973B (zh) 2023-08-15
CA3068045A1 (en) 2019-01-03
AU2018295118B2 (en) 2025-04-17
IL271257B2 (en) 2024-11-01
CN116041530A (zh) 2023-05-02
WO2019005639A2 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
CN110891650B (zh) 制导和导航控制蛋白及其制造和使用方法
KR102763369B1 (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
KR102837521B1 (ko) Bcma에 결합하는 항체 및 이의 용도
KR102838340B1 (ko) 다중-특이적 항체 및 이들의 제조 및 사용 방법
AU2018250301B2 (en) Anti-ICOS agonist antibodies and uses thereof
CN106459203B (zh) 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
JP7750887B2 (ja) 癌免疫療法のための併用療法での多重特異性抗体
CN113939536B (zh) Tigit和pd-1/tigit-结合分子
RU2730674C2 (ru) Антитела, связывающиеся с человеческим каннабиноидным рецептором 1 (св1)
KR20220033522A (ko) 항-cd73 항체와의 조합 요법
CN110869390B (zh) 抗pd-l1抗体及其用途
KR20180082563A (ko) 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
KR20170091179A (ko) Fap 및 dr5에 특이적인 이중특이성 항체, dr5에 특이적인 항체 및 사용 방법
KR102558418B1 (ko) Pd-1에 결합하는 항체 및 그 용도
CN110869392A (zh) 用抗gitr激动性抗体治疗癌症
KR20220160555A (ko) Cd40에 결합하는 항체 및 이의 용도
AU2016330471A1 (en) Antibodies that bind human cannabinoid 1 (CB1) receptor
TW202313110A (zh) 癌症之治療
RU2837770C2 (ru) Мультиспецифические антитела и способы их получения и применения
RU2811477C2 (ru) Мультиспецифические антитела и способы их получения и применения
HK40018991B (zh) 多特异性抗体及其制备和使用方法
RU2773758C2 (ru) Связывающиеся с pd-1 антитела и способы их применения
RU2812280C1 (ru) Связывающиеся с pd-1 антитела и способы их применения
HK40019010B (zh) 多特异性抗体及其制备和使用方法
CN117460529A (zh) 抗icos抗体的用途

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250131

Application number text: 1020207002328

Filing date: 20200122

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250228

Comment text: Request for Examination of Application